TYVERB, known generically as lapatinib, is a targeted therapy medication used in the treatment of certain types of breast cancer. Specifically, it is designed for patients whose tumors overexpress the HER2/neu receptor, a protein that promotes the growth of cancer cells. TYVERB works by inhibiting the action of the HER2/neu protein and the epidermal growth factor receptor (EGFR), thereby slowing down or stopping the growth and spread of cancer cells. It is often used in combination with other chemotherapy drugs to enhance its effectiveness. As an oral medication, TYVERB offers a convenient option for patients, but it also comes with potential side effects that require monitoring by healthcare professionals. Its use is critical in the management of advanced or metastatic breast cancer, providing a targeted approach that can lead to improved outcomes for patients with specific cancer profiles.